Aids Vaccine Advocacy Coalition
- Assets
- $6.2m
- Revenue
- $10.8m
- Investments
- $0.0
- Employees
- 34
- Location
- New York, NY
- Founding
- 04/1997
- Data as of
- 12/2021
- EIN
- 94-3240841
Organization Overview
Aids Vaccine Advocacy Coalition is located in New York, NY. The organization was established in 1997. According to its NTEE Classification (P20) the organization is classified as: Human Service Organizations, under the broad grouping of Human Services and related organizations. As of 12/2021, Aids Vaccine Advocacy Coalition employed 34 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Aids Vaccine Advocacy Coalition is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Aids Vaccine Advocacy Coalition generated $10.8m in total revenue. This organization has experienced exceptional growth, as over the past 7 years, it has increased revenue by an average of 10.2% each year . All expenses for the organization totaled $13.8m during the year ending 12/2021. While expenses have increased by 14.7% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Aids Vaccine Advocacy Coalition has awarded 55 individual grants totaling $25,120,721. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
AIDS VACCINE ADVOCACY COALITION (AVAC) IS AN INTERNATIONAL NON-PROFIT (CONTINUED ON SCHEDULE O)CONTINUED: ORGANIZATION THAT USES PUBLIC EDUCATION, POLICY ANALYSIS, ADVOCACY AND COMMUNITY MOBILIZATION TO ACCELERATE THE ETHICAL DEVELOPMENT AND GLOBAL DELIVERY OF AIDS VACCINES AND OTHER PREVENTION TECHNOLOGIES AND INTERVENTIONS. RESOURCES FOR HIV VACCINE AND PREVENTION RESEARCH BY GOVERNMENT AGENCIES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
PRODUCT INTRODUCTION AND ACCESS: THE PRODUCT INTRODUCTION PROGRAM IS DESIGNED TO IDENTIFY AND ANTICIPATE NEEDS AND GAPS AND PROVIDE TARGETED TOOLS, SUPPORT AND PLATFORMS TO EXPAND ACCESS TO HIV/AIDS PREVENTION. THE PROGRAM FOCUSES ON: SUCCESSFUL SCALE-UP AND INTRODUCTION IN THREE PRIORITY COUNTRIES FROM THE OUTSET; DEVELOP ADAPTABLE AND SCALABLE TOOLS TO SUPPORT OTHER COUNTRIES; SUPPORT THE DEVELOPMENT OF MARKETABLE PRODUCTS IN THE HIV PREVENTION RESEARCH PIPELINE; AND CREATE A FLEXIBLE MECHANISM TO ASSIST PRODUCT DEVELOPERS, FUNDERS AND COUNTRY PROGRAMS TO IDENTIFY AND ADDRESS BARRIERS TO IMPROVED PRODUCTS AND ACCELERATEDINTRODUCTION. (CONTINUED ON SCHEDULE O) CONTINUED: THE PROJECT IS IMPLEMENTED IN COLLABORATION WITH ONE PRIMARY SUBGRANTEE THE CLINTON HEALTH ACCESS INITIATIVE (CHAI), FINAL MILE WHO FOCUSES ON END USER RESEARCHAND POPULATION SERVICES INTERNATIONAL (PSI) THAT SUPPORTS END USER RESEARCH IN SOUTH AFRICA.
RESEARCH ENGAGEMENT AND PREPAREDNESS: RESEARCH PREPAREDNESS IS DESIGNED TO SHAPE THE R&D ENVIRONMENT THROUGH ADVOCACY FOR INVESTMENT, POLITICAL SUPPORT, AND GOOD PARTICIPATORY PRACTICE. AVAC DEVELOPED MATERIALS AND DOCUMENTS RELATING TO THE PREVENTION OF HIV/AIDS; CONVENED MULTIPLE MEETINGS WITH STAKEHOLDERS SUCH AS RESEARCHERS AND CIVIL SOCIETY LEADERS TO DISCUSS RESEARCH FINDINGS AND ISSUED SUBGRANTS TO 8 PARTNERS IN THE US AND AFRICA UNDER THE HIV BIOMEDIAL PREVENTION RESEARCH PROJECT FUNDED BY USAID: (CONTINUED ON SCHEDULE O) CONTINUED: NEW HIV MICROBICIDES ADVOCACY SOCIETY (NHVMAS) IN NIGERIA, AVENIR HEALTH, FHI 360, INTERNATIONAL AIDS VACCINE INITIATIVE (IAVI) AND INTERNEWS IN THE US, HIV/AIDS VACCINE ETHICS GROUP OF THE UNIVERSITY OF KWAZULU - NATAL (HAVEG), WITS REPRODUCTIVE HEALTH AND HIV PREVENTION (WITS) AND WACI HEALTH IN SOUTH AFRICA. AVAC ALSO ISSUED SUBGRANTS TO CLI, TNCA, MESHA, CCI, PAKACHERE, HEALTH GAP, ICW-EA, HEJNU, ZAMCOM, ZAN. IT ALSO INCLUDES $2,500 IN DISCRETIONARY FUNDS TO FELLOWS AND RX ROAR MEMBERS.
IMPLEMENTATION ADVOCACY: THE IMPLEMENTATION ADVOCACY PROGRAM WHERE AVAC PROVIDES TECHNICAL SUPPORT IS DESIGNED TO IMPROVE EVIDENCE-BASED AND RIGHTS-BASED DONOR AND GOVERNMENT INVESTMENTS IN A COMPREHENSIVE RESPONSE TO THE HIV/AIDS EPIDEMIC.
PROGRAMS ARE STRENGTHENING GLOBAL ADVOCACY, POLICY DATA AND ANALYTICS AND PROGRAM MANAGEMENT AND COORDINATION.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Mitchell Warren Executive Director | OfficerTrustee | 50 | $365,375 |
Erin Kiernon Chief Operating Officer | Officer | 40 | $237,547 |
Jessica Rodrigues Director: Product Introduction | 40 | $202,323 | |
Abigail Smith Chief Financial Officer | Officer | 40 | $200,386 |
Kevin Fisher Director: Policy, Data & Analytics | 40 | $196,074 | |
Manju Chatani Director: Partnerships & Capacity Strengthening | 40 | $171,100 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Global Health Visions Support For Avac's Strategic Planning Pr | 12/30/21 | $143,124 |
Kay Marshall Communication Services | 12/30/21 | $196,188 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $5,731,067 |
| All other contributions, gifts, grants, and similar amounts not included above | $5,055,651 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $10,786,718 |
| Total Program Service Revenue | $0 |
| Investment income | $2,701 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $10,789,806 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $2,346,253 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $3,071,204 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $977,948 |
| Compensation of current officers, directors, key employees. | $184,674 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $3,489,690 |
| Pension plan accruals and contributions | $121,358 |
| Other employee benefits | $930,078 |
| Payroll taxes | $273,705 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $12,294 |
| Fees for services: Accounting | $74,500 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $1,768,010 |
| Advertising and promotion | $0 |
| Office expenses | $176,487 |
| Information technology | $95,254 |
| Royalties | $0 |
| Occupancy | $113,987 |
| Travel | $35,277 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $63,238 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $3,077 |
| Insurance | $24,090 |
| All other expenses | $0 |
| Total functional expenses | $13,757,513 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $1,219,744 |
| Savings and temporary cash investments | $3,861,782 |
| Pledges and grants receivable | $1,080,083 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $23,422 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $6,185,031 |
| Accounts payable and accrued expenses | $474,016 |
| Grants payable | $586,469 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $1,060,485 |
| Net assets without donor restrictions | -$12,424 |
| Net assets with donor restrictions | $5,136,970 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $6,185,031 |
Grants Awarded
Over the last fiscal year, Aids Vaccine Advocacy Coalition has awarded $2,297,412 in support to 10 organizations.
| Grant Recipient | Amount |
|---|---|
Boston, MA PURPOSE: TO CREATE A PLATFORM | $919,354 |
New York, NY PURPOSE: HIV VACCINE AND BIOM | $320,750 |
New York, NY PURPOSE: TO INCREASE THE ACCO | $279,628 |
Arcata, CA PURPOSE: HIV VACCINE AND BIOM | $260,801 |
FINAL MILE PURPOSE: TO CONDUCT QUALITATI | $218,284 |
Durham, NC PURPOSE: HIV VACCINE AND BIOM | $160,225 |
Grants Recieved
Over the last fiscal year, we have identified 12 grants that Aids Vaccine Advocacy Coalition has recieved totaling $10,439,416.
| Awarding Organization | Amount |
|---|---|
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $3,300,000 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $2,700,000 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $2,251,722 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $721,726 |
Bill & Melinda Gates Foundation Seattle, WA PURPOSE: HIV | $721,726 |
Rockefeller Foundation New York, NY PURPOSE: IN SUPPORT OF BUILDING CAPACITY AMONG JOURNALISTS IN SOUTHERN AND EASTERN AFRICA TO ENSURE MORE ACCURATE AND EVIDENCED-BASED COVERAGE ABOUT COVID-19 VACCINES | $500,000 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Community Renewal Team Inc Hartford, CT | $32,612,649 | $50,680,669 |
Valley Opportunity Council Inc Chicopee, MA | $22,850,959 | $49,579,644 |
Jewish Community Council Of Greater Coney Island Inc Brooklyn, NY | $14,065,313 | $45,116,234 |
Elrc4kids Inc Greensburg, PA | $6,335,708 | $42,009,228 |
Greater Bergen Community Action Inc Hackensack, NJ | $31,538,152 | $42,343,270 |
Ezras Choilim Health Center Inc Monroe, NY | $23,435,027 | $45,592,726 |
Metropolitan New York Coordinating Council On Jewish Poverty New York, NY | $56,489,415 | $47,513,181 |
Puerto Rican Family Institute Inc New York, NY | $23,494,373 | $43,970,504 |
Worcester Community Action Council Inc Worcester, MA | $8,882,298 | $41,343,806 |
Educational Alliance Inc New York, NY | $44,753,122 | $39,086,207 |
Catholic Charitable Bureau Of The Archdiocese Of Boston Inc South Boston, MA | $52,520,056 | $42,947,634 |
Catholic Charities- Diocese Of Metuchen Perth Amboy, NJ | $28,793,391 | $35,804,723 |